[PDF] Top 20 Turismo rural y desarrollo local en Cuba

... with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR ... See full document

... that CD20, PAX-5, CD23, SIg, and Bcl-2 were positive; SOX-11, CD3, CD5, MPO, CD34, CD10, Bcl-6, MUM-1, LEF-1 or CyclinD1 were negative, and Ki-67 stain- ing revealed a proliferative index of 10% (Figure ...for ... See full document

... nous leukemia cell lines [30] and CLL cells [31], they are unsuitable for CLL therapy because statins interfere with the detection of CD-20 and impair rituximab-mediated complement-dependent cytotoxicity ... See full document

... lymphoma (B-NHL) subtypes, including diffuse large B- cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) [4–7]. In these entities, BCR ... See full document

... marker), CD20/CD79a (B-cell markers), CD23 (B-cell chronic lymphocytic leukemia/lymphoproliferative dis- ease marker), CD21 (mature B-cell and follicular dendritic cell marker), CD35 ... See full document

... A further promising option in the treatment of CLL is the combination of monoclonal antibodies and ibrutinib. The consideration behind this is the clearance of CLL cells from peripheral blood by, for example, a ... See full document

... The combination regimen, composed of the purine analog fludarabine (F), the alkylating agent cyclophosphamide (C), and the human- ized anti-CD20 monoclonal antibody rituximab (R), has emerged as a highly effective ... See full document

... Triptolide, a small molecule inhibitor of HSF1, is a diterpenoid epoxide isolated from the Chinese herb Tripterygium wilfordii. Triptolide and its derivatives have demonstrated anti-cancer activity against several ... See full document

... Chronic lymphocytic leukemia (CLL) is the most com- mon B-cell neoplasm in Europe and United States, char- acterized by progressive accumulation of monoclonal CD5+ B cells in peripheral blood, bone ... See full document

... selectively targeting the Mir15a/16-1 cluster within intron 4 of the Dleu2 gene, and the third line carries a relatively large deletion spanning the genomic region most commonly deleted in 13q14 and including ... See full document

... blastic leukemia (CLL), which have been replaced by monoclonal antibodies, such as rituximab in the past 10 years for refractory or relapsed ...updated CD20 antibody, that is thought to achieve a more ... See full document

... It has been reported that expression of miR-155 can alter the signaling pathways triggered by BCR response by modulating the expression of SHIP1 in CLL. SHIP1 encodes for Src homology-2 domain containing inositol ... See full document

... Abstract: Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody ritux- imab ... See full document

... Therapeutically targeting the FOXO signaling pathway(s) could lead to the discovery and development of efficacious agents against some cancers, but this requires an enhanced understanding and knowledge of FOXO ... See full document

... Despite the usual uniformity, cases of MCL with morphologic, immunophenotypic, genetic and clinical heterogeneity have been documented. Pleomorphic or blastoid variants of MCL usually have additional genetic changes and ... See full document

... A 55-year-old male was admitted to our hema- tological department in April 2014 with asthma and abdominal mass for 2 months. His past medical history revealed HL41 months ago. Personal history: He smoked one pack of ... See full document

... In the era of cancer epigenetics, Alu methylation in- vestigation may be important not only to evaluate the global DNA methylation variations in disease, and the impact of Alu epigenetic variations on gene expression and ... See full document

... In chronic lymphocytic leukemia (CLL), molecular characterization by high-throughput technologies are redefining risk groups and paving the way for truly individualized treat- ment strategies, based ... See full document

... transformed chronic-phase chronic myeloid leukemia (CML-CP) from a lethal can- cer into a chronic disorder that is compatible with a largely normal span and quality of ... See full document

... pleomorphic neoplastic cells, most of which were large, and round to oval in shape. Some neoplastic giant cells were observed. The cytoplasm was usually abundant, and the nuclei were generally large and round with a ... See full document